Yuliang
Yuliang Deng, Hangzhou CN
Patent application number | Description | Published |
---|---|---|
20130124421 | SECURE AUTHENTICATION METHOD AND SYSTEM FOR ONLINE TRANSACTIONS - Embodiments of the invention relate to a secure authentication method for online transactions, an online transaction secure authentication system, an online transaction secure authentication client, and a computer program product for secure authentication of online transactions thereof. The secure authentication method includes: generating, using one or more computer processors, a random session key to encrypt communications between a client and a server; verifying a user identity of a user using the client based on the generated random session key; in the event that the verification of the user identity is successful, generating transaction image information, encrypting the transaction image information based on the random session key, and transmitting the encrypted transaction image information to the client; receiving a confirmation of the transaction image information, the confirmation comprising a transaction signature; and verifying the transaction signature based on the random session key. | 05-16-2013 |
Yuliang Huang, Shanghai CN
Patent application number | Description | Published |
---|---|---|
20110293554 | RECOMBINANT HUMAN G-CSF DIMER AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES - This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased. | 12-01-2011 |
20130165637 | USE OF G-CSF DIMER IN THE TREATMENT OF NEUTROPENIA - This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia. | 06-27-2013 |
20130171100 | USE OF INTERLEUKIN-22 IN TREATING VIRAL HEPATITIS - This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis. | 07-04-2013 |
20140004076 | RECOMBINANT HUMAN G-CSF DIMER AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES | 01-02-2014 |
20140248234 | USE OF G-CSF DIMER IN PREPARATION OF MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease. | 09-04-2014 |
20150147290 | USE OF G-CSF DIMER IN THE TREATMENT OF NEUTROPENIA - This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia. | 05-28-2015 |
20150147293 | USES OF INTERLEUKIN-22(IL-22) IN TREATING AND PREVENTING NERVE DAMAGE DISEASES OR NEURODEGENERATIVE DISEASES - This invention discloses the uses of IL-22 in the treatment and prevention of a nerve damage disease or a neurodegenerative disease. In particular, the invention discloses the uses of IL-22 or IL-22 dimers as follows: (i) can protect neurons to recover the functions of injured neurons after ischemic nerve damage in animals in vivo, thus enabling effective treatment of nerve damage diseases, (ii) can significantly inhibit the loss of dopaminergic neurons in substantia nigra in PD model animal, enhance the functions of dopaminergic neurons, significantly reduce neuronal apoptosis in hippocampus, improve learning and memory capacity of AD model rats, and effectively prevent neuronal loss, thereby enabling more effective treatment of neurodegenerative diseases. | 05-28-2015 |
20150202267 | USE OF INTERLEUKIN-22 IN TREATING VIRAL HEPATITIS - This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by heptatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis. | 07-23-2015 |
Yuliang Liu, Beijing CN
Patent application number | Description | Published |
---|---|---|
20140018380 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS - The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula I, pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof. | 01-16-2014 |
Yuliang Qian, Jiangsu CN
Patent application number | Description | Published |
---|---|---|
20160081471 | SUPPORTING STRUCTURE AND LOADING-TRANSPORTING METHOD OF STORAGE AND TRANSPORT CONTAINER - A supporting structure ( | 03-24-2016 |
Yuliang Sun, Botou CN
Patent application number | Description | Published |
---|---|---|
20140058625 | MULTI-FUNCTION VEHICLE-ROLLOVER JUDGMENT SYSTEM AND AUTOMATIC ANTI-ROLLOVER DEVICE - This invention public a multi-functional rollover judgment system and automatic anti-rollover device which are all belong to vehicle area. The mentioned system at least includes two displacement sensors and ECU which is connected with mentioned sensors correspondingly, and the output device (connected with ECU). The mentioned displacement sensor is distributed by a group of two, and at least one group mentioned displacement sensor is set between the frame and axle symmetrically. The mentioned device includes multi-functional judgment system and its connected actuator, and the mentioned actuator at least includes left actuator and right actuator which are symmetrically set on the frame. Both of the mentioned left actuator and right actuator include a telescopic shaft and the return wheel which is set on the outside of telescopic shaft. The invention can prevent the rollover accident from happening in any condition and have wide application range & high accuracy. | 02-27-2014 |
Yuliang Wang, Shanghai CN
Patent application number | Description | Published |
---|---|---|
20120041058 | COMPOSITION OF TRADITIONAL CHINESE MEDICINE FOR REDUCING BLOOD FAT AND PREPARATION METHOD THEREOF - Composition of traditional Chinese medicine for reducing blood lipid with components of the crude drug of artemisinins and the crude drug of ursolic acid, wherein the ratio of the crude drug of artesunate and the crude drug of ursolic acid is 1:25-25:1 by weight. The preparation method of such composition includes the following steps: the crude drug of artesunate and the crude drug of ursolic acid are mixed at the weight ratio mentioned above, comminuted, then screened through 120 mesh sieve to obtain the composition; or the crude drug of artesunate and the crude drug of ursolic acid are weighed at the weight ratio mentioned above, comminuted, screened through 120 mesh sieve separately, then mixed and screened for three times to obtain the composition. The composition of the present invention can be formulated into formulations for injection, oral administration with pharmaceutically acceptable carriers, and can be used for preparing medicaments for reducing blood lipid. | 02-16-2012 |
Yuliang Wang, Shijiazhuang CN
Patent application number | Description | Published |
---|---|---|
20080319163 | Method for Isolating and Purifying Immuno-Modulating Polypeptide from Cow Placenta - The present invention provides a method for isolating and purifying immuno-modulating polypeptide from cow placenta, which is characterized by using the steps of anion-exchange chromatography, gel exclusion chromatography and reverse-phase high performance liquid chromatography to isolate and purify immuno-modulating polypeptide from cow placenta, identifying its activity of stimulating lymphocyte proliferation in vitro by MTT method, then determining its molecular weight by MALDI-TOF-MS, its isoelectric point by CIEF and its amino acid sequence with analyzer for protein sequencing. Since the obtained immuno-modulating polypeptide by the method according to the present invention has more than 90% purity, its bioactivity can reach medicinal standards. | 12-25-2008 |
Yuliang Xu, Jiaxing CN
Patent application number | Description | Published |
---|---|---|
20140284938 | GRAVITATIONAL ENERGY CONVERSION DEVICE AND APPLICATION THEREOF - The invention discloses a gravitational energy conversion device, comprises a device frame, a weight, a luggage carrier, a combined spring, a chain, a ratchet wheels, a transmission shaft, flywheels, a limit latch, and a return spring. The transmission shaft is arranged on the device frame. The flywheels are arranged at both ends of the transmission shaft. The ratchet wheels are arranged on the transmission shaft. The ratchet wheels engage with the chain. One end of the chain is fixed to the limit latch, and the other end is connected to one end of the combined spring. Pairs of pawls which match the limit latch are arranged on inner sidewalls of the device frame in the same horizontal plane. One end of the return spring is fixed to the limit latch, and the other end is fixed to the luggage carrier. | 09-25-2014 |
Yuliang Zhang, Dalian CN
Patent application number | Description | Published |
---|---|---|
20120037541 | Multi-Metallic bulk catalyst with layered structure and method for the preparation and use thereof - The invention discloses a multi-metallic bulk catalyst with layered structure, wherein the metals in the multi-metallic bulk catalyst is consisted of a Group VIII metal M | 02-16-2012 |
Yuliang Zhao, Beijing CN
Patent application number | Description | Published |
---|---|---|
20090076171 | Metallofullerols and their Applications for Preparation of Medicine for Inhibition of Tumor Growth - This invention provides a composition of polyhydroxylated metallofullerene compound and its application in the preparation of antitumor pharmaceutical. In one embodiment, metallofullerol comprising the formula, M@C | 03-19-2009 |
20140217277 | METHOD AND KIT FOR DETECTING HEPCIDIN - A method for detecting hepcidin. Having a sample liquid in contact with a nanochip having a specific surface coating structure of silicon oxide, so that hepcidin is enriched with specificity; eluting the nanochip with an eluent; by performing mass spectrometric detection on the elution product, determining the hepcidin content in the elution product. The enrichment method substantially enhances the sensitivity and accuracy of mass spectrometric detection. A kit for detecting hepcidin comprising a sample diluent and a nanochip, the sample diluent comprising water, trifluoroacetic acid, and acetonitrile. | 08-07-2014 |
Yuliang Zheng, Shanghai CN
Patent application number | Description | Published |
---|---|---|
20160029715 | FACE MASK STRUCTURE HAVING BARRIER COMPONENT - A mask structure includes a mask body having at least one edge side; at least one subsidiary part connecting with and corresponding to the edge side, wherein an angle is formed between the subsidiary part and the mask body; and a band set fixing at the two sides of the mask body. | 02-04-2016 |
Yuliang Zheng, Charlotte, NC US
Patent application number | Description | Published |
---|---|---|
20100017859 | Authentication system for networked computer applications - A system such as in a networked computer system comprising a user, an application server, a gatekeeper server and an authentication server. Communication within the system is managed by the gatekeeper server, wherein the user communicates with the authentication server and the application server through the gatekeeper server. Once the user has been initially authenticated by the authentication server, the user may request application services from a plurality of application servers within the networked computer system without having to be re-authenticated. | 01-21-2010 |
20110058673 | PUBLIC KEY ENCRYPTION FOR GROUPS - A system is comprised of a user and a group, wherein the group is comprised of a group leader and a group of M members where M is equal to or greater than one. The group leader generates a group public key and a group leader “master” private key. The group leader creates a personalized watermarked or decryption key, also referred to as an individual private key, for each group member. The individual private key uniquely identifies each group member. The group leader distributes the individual private keys to each of the group members. Each group member receives from a user a message encrypted using the group public key. Each of the group members uses its individual private key to decrypt the encrypted message sent by the user to the group. | 03-10-2011 |
20120179911 | CRYPTOGRAPHIC KEY BACKUP AND ESCROW SYSTEM - A system for securely storing application keys is comprised of a database system, a peripheral hardware security module and cryptographic keys, wherein cryptographic keys comprise application keys, intermediate keys and a master key. Application keys are grouped according to characteristic and are associated with a particular intermediate key, which is utilized to scramble and descramble application keys within the associated group. Intermediate keys are associated with the master key, which is utilized to scramble and descramble the intermediate keys. Scrambling and descrambling of keys is performed within the peripheral hardware security module. | 07-12-2012 |